Acute Myeloid Leukaemia

2020 ◽  
pp. 124-133
Author(s):  
Gertjan Kaspers ◽  
Dirk Reinhardt
Keyword(s):  
Down Syndrome ◽  
Stem Cell ◽  
Prognostic Factors ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Residual Disease ◽  
Study Groups ◽  
Cooperative Study ◽  
Minimal Residual ◽  
Acute Myeloid

Acute myeloid leukaemia (AML) is the second most frequent type of leukaemia in children, and is cured nowadays in about 75% of patients in settings with essentially unlimited resources. This chapter discusses the aetiology and epidemiology of this interesting disease, its typical clinical presentation, diagnostics, and biology. The classifications, prognostic factors, and risk stratification (including minimal residual disease), and AML treatment (covering chemotherapy and allogeneic stem-cell transplantation) is presented. Several practical illustrations are included, and results of recent studies from the main cooperative study groups are summarized. Finally, side effects during treatment and late effects, as well as acute promyelocytic leukaemia (APL) and myeloid leukaemia of Down syndrome (ML-DS), are discussed. The chapter concludes with the actual challenges and perspectives.

Myelodysplastic Syndrome, Myeloid Leukaemia of Down Syndrome, and Juvenile Myelomonocytic Leukaemia

2020 ◽  
pp. 134-141
Author(s):  
Henrik Hasle ◽  
Charlotte M. Niemeyer
Keyword(s):  
Bone Marrow ◽  
Down Syndrome ◽  
Stem Cell ◽  
Acute Myeloid Leukaemia ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukaemia ◽  
Clinical Characteristics ◽  
Bone Marrow Failure ◽  
Signal Pathways ◽  
Acute Myeloid

Myeloid malignancies in children are divided into acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS), juvenile myelomonocytic leukaemia (JMML), and the myeloid leukaemia of Down syndrome (ML-DS). Predisposing genetic conditions are common in MDS. Differentiating MDS from inherited bone marrow failure or AML may be challenging. Therapy consists of observation, immunosuppression, or stem-cell transplantation (SCT). Germline and somatic mutations deregulating the Ras/MAPK signal pathways are key initiating events in JMML. Genetics in JMML defines clinically relevant subgroups and indications for SCT. ML-DS presents with unique clinical characteristics and responds favourably to reduced doses of AML chemotherapy; however, relapse is often refractory to therapy.

Feasibility ofBAALCgene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemia

2016 ◽  
Vol 175 (5) ◽  
pp. 904-916 ◽  
Author(s):  
Simone Weber ◽  
Torsten Haferlach ◽  
Tamara Alpermann ◽  
Karolína Perglerová ◽  
Susanne Schnittger ◽  
...  
Keyword(s):  
Risk Stratification ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Normal Karyotype ◽  
Minimal Residual ◽  
Acute Myeloid

scholarly journals Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

2010 ◽  
Vol 11 (6) ◽  
pp. 543-552 ◽  
Author(s):  
Jeffrey E Rubnitz ◽  
Hiroto Inaba ◽  
Gary Dahl ◽  
Raul C Ribeiro ◽  
W Paul Bowman ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Minimal Residual Disease ◽  
Multicentre Trial ◽  
Residual Disease ◽  
Minimal Residual ◽  
Acute Myeloid

scholarly journals Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease.

1996 ◽  
Vol 49 (1) ◽  
pp. 15-18 ◽  
Author(s):  
A Macedo ◽  
J F San Miguel ◽  
M B Vidriales ◽  
M C Lopez-Berges ◽  
M A Garcia-Marcos ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Phenotypic Changes ◽  
Minimal Residual ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document